TD Cowen analysts adjusted their outlook on Biogen (NASDAQ:BIIB) shares, reducing the price target to $200 from the previous $275, while sustaining a Buy rating on the stock. The revision reflects ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers ...

Reddit stock is down Thursday after the social media platform fell short of expectations on a key metric for its fourth ...

The company has reportedly reinitiated discussions with Indian policymakers and regulators, including the Financial ...

Robinhood stock is sizzling Thursday after the online trading platform reported impressive fourth-quarter results. Here's ...